Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 405 participants.

Also called NCT01226043

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 405 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01226043
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01226043. Randomized; no masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2013-07-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus
Acronym
Pen Preference
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin Glargine
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01226043
Content hash
44b98d20d140fcad2cc997bf461077cc40affc21eb8310436a0dd5f28c5ebfe8